Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 210

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 210
---
 to enhance efficacy and tolerability. Below are two investigational therapies advancing through clinical trials:

MEDI7352 – AstraZeneca

MEDI7352 is a first-in-class bispecific monoclonal antibody (mAb) designed to simultaneously inhibit nerve growth factor (NGF) and tumor necrosis factor (TNF), two key mediators in the pathophysiology of chronic pain. Bispecific antibodies offer dual-targeting capabilities, potentially enhancing therapeutic efficacy by modulating multiple pain pathways.

Currently in Phase II clinical trials, MEDI7352 is being evaluated for its efficacy and safety in patients with painful diabetic neuropathy (PDN). The program reflects AstraZeneca’s strategic investment in novel biologics to address chronic pain conditions, particularly where standard pharmacotherapies fall short.

CNTX-6016 – Centrexion Therapeutics

CNTX-6016 is a highly selective cannabinoid receptor type 2 (CB2) agonist for its analgesic potential in neuropathic pain. Unlike CB1 receptors, CB2 receptors are primarily expressed in immune cells and peripheral tissues, allowing for pain relief without central nervous system side effects such as psychoactivity or sedation.

The compound is in Phase IIa clinical trials, focused on assessing safety, tolerability, and pharmacokinetics in healthy volunteers and a subset of patients with painful diabetic neuropathy. Its novel mechanism positions it as a differentiated candidate in the cannabinoid-based therapeutic space.

CNTX-6016 may appeal to clinicians and patients seeking non-opioid, non-GABAergic alternatives with reduced risk of abuse or cognitive impairment, offering potential market advantage in the chronic pain segment.

Diabetic Neuropathy Market Size

According to Precedence Research 2, the global diabetic neuropathy market was valued at USD 4.50 billion in 2024 and is projected to reach approximately USD 9.06 billion by 2034, reflecting a compound annual growth rate (CAGR) of 7.24% from 2025 to 2034. This growth is primarily driven by the rising prevalence of diabetic neuropathy, particularly among the aging diabetic population, coupled with ongoing advancements in the development of innovative therapeutics aimed at addressing this condition.

2Diabetic Neuropathy Market Size, Share and Trends 2025 to 2034, Precedence Research, Updated January 2025

| Moore Financial Consulting |

| MIRA Pharmaceuticals, Inc. | April 2025    |
| Valuation                  | Page 11 of